Mode
Text Size
Log in / Sign up

Oral celecoxib plus flurbiprofen hydrogel patch improves lateral epicondylitis outcomes versus celecoxib alone in a retrospective cohortPain Relief for Tennis Elbow Gets a Boost

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider combined celecoxib and flurbiprofen hydrogel patch for lateral epicondylitis, noting faster relief and higher efficacy in this retrospective cohort.

This retrospective cohort analysis evaluated 64 patients diagnosed with lateral epicondylitis in a real-world setting. The study compared oral celecoxib combined with flurbiprofen hydrogel patch against oral celecoxib alone. Outcomes were assessed at pre-treatment, 2 weeks, and 4 weeks of treatment, with a 3-month follow-up for recurrence rates.

At 2 weeks post-treatment, the combined therapy group showed significantly lower VAS scores (3.9 ± 1.4 vs. 5.0 ± 1.5, P = 0.003) and PRTEE scores (37.8 ± 10.5 vs. 46.3 ± 12.1, P = 0.004) compared to the celecoxib-alone group. By 4 weeks, VAS scores remained lower (2.2 ± 1.1 vs. 3.6 ± 1.3, P < 0.001) and PRTEE scores were reduced (21.0 ± 9.8 vs. 31.4 ± 10.9, P < 0.001).

The combined regimen demonstrated a higher overall efficacy rate (81.3% vs. 59.4%, P = 0.049) and faster effecting time (median: 4.0 days vs. 7.0 days, P = 0.003). Serum inflammatory markers, including TNF-α (12.3 ± 3.5 pg/mL vs. 16.8 ± 4.1 pg/mL, P < 0.001), IL-6 (8.1 ± 2.9 pg/mL vs. 11.7 ± 3.3 pg/mL, P < 0.001), and CRP (5.2 ± 2.1 mg/L vs. 8.0 ± 2.8 mg/L, P < 0.001), were significantly lower in the combined group at 4 weeks.

Safety analysis revealed no significant difference in the overall incidence of adverse events between groups (21.9% vs. 12.5%, P = 0.327). Serious adverse events, discontinuations, and tolerability were not reported as significantly different. The 3-month recurrence rate was not significantly different (15.6% vs. 34.4%, P = 0.085). While the combined regimen offers potential benefits, the observational nature of this analysis prevents definitive causal conclusions.

  • Adds a patch to pills for faster healing
  • Helps people with stubborn elbow pain
  • Ready now — doctors can use it today

This combo cuts pain and inflammation better than pills alone.

You’ve had that nagging ache on the outside of your elbow for weeks. Maybe you lifted something heavy. Maybe you play tennis. Or maybe it just started one day and won’t go away. You try rest. Ice. Over-the-counter painkillers. But the pain lingers, making simple tasks — like holding a coffee cup or turning a doorknob — a challenge.

Now, a new real-world study offers fresh hope for faster relief — not with a new drug, but with a smarter way of using two old ones.

Why it hurts so much

Lateral epicondylitis — better known as tennis elbow — isn’t just for athletes. It affects office workers, parents, gardeners, anyone who repeats wrist and arm motions. The condition happens when tendons in the elbow get tiny tears from overuse.

It’s more common than you think. Up to 3% of adults will get it. Most recover in 6 to 12 months, but the pain can be brutal while it lasts. And current treatments? They often fall short.

Pills like ibuprofen or celecoxib help some, but not all. Shots and physical therapy work for others — but not right away. Many people just wait it out, hoping it gets better on its own.

That’s why better pain control — faster — matters.

Old fix, new twist

For years, doctors have prescribed oral anti-inflammatory drugs like celecoxib. It helps reduce swelling and pain inside the body. But it works system-wide, which means more strain on the stomach and liver — and slower results at the actual injury site.

Here’s the twist: what if you could attack the pain right where it hurts — and also from the inside?

That’s exactly what this study tested.

Double-duty pain control

Think of inflammation like a fire. Oral meds are like sending a fire truck from headquarters — it helps, but it takes time to arrive. The flurbiprofen patch is like a firefighter already on the scene, spraying water directly on the flames.

The patch sticks to the skin over the elbow. It slowly releases medicine that sinks deep into the sore tendons. Meanwhile, the pill works from the bloodstream to calm overall inflammation.

Together, they hit the problem from two angles.

Researchers looked back at 64 patients treated for tennis elbow between 2022 and 2024. Half took celecoxib pills only. The other half used the pills plus the flurbiprofen patch.

Everyone was checked at 2 and 4 weeks for pain, function, and blood signs of inflammation.

Big drop in pain — fast

At 2 weeks, the combo group had much lower pain scores. Their average pain dropped to 3.9 (out of 10), compared to 5.0 in the pill-only group.

By 4 weeks, the difference was even clearer: 2.2 vs. 3.6.

That’s not just a number. That’s the difference between wincing when you lift your arm — and being able to carry groceries again.

They also scored better on daily function. Tasks like gripping, lifting, and twisting became easier, much sooner.

This doesn’t mean this treatment is available yet.

Wait — it already is.

Faster relief, fewer flare-ups

The combo group felt better in just 4 days on average. The pill-only group took 7.

That’s 3 fewer days of pain — a big win when you’re struggling to work or sleep.

The combo also had an 81% success rate, compared to 59% with pills alone.

And while not statistically significant, the recurrence rate at 3 months was less than half: 15.6% vs. 34.4%. That suggests longer-lasting relief — though more research is needed to confirm.

Inflammation drops in blood tests

Here’s something surprising: the patch didn’t just help locally. It showed up in blood tests.

Patients using the combo had much lower levels of TNF-α, IL-6, and CRP — key markers of body-wide inflammation.

At 4 weeks, CRP levels were 5.2 vs. 8.0 — a drop that signals the body is calming down, not just numbing the pain.

This suggests the patch may boost the pill’s power — not just add to it.

But there’s a catch

Safety was similar in both groups. About 1 in 5 in the combo group had side effects — mostly mild skin irritation from the patch. The pill-only group had fewer issues, but the difference wasn’t significant.

No serious stomach or liver problems were reported. That’s good news, since oral NSAIDs can sometimes cause those.

Still, this was a small study. And it looked back at past cases — not a randomized trial.

What experts see

This fits a growing trend: combining treatments for better results, without more risk. Topical NSAIDs are already recommended in some guidelines — but often as a second choice.

This study suggests they should be considered earlier — especially for people who need fast relief or can’t tolerate strong pills.

It’s not a cure. But it’s a smarter way to use tools we already have.

If you have tennis elbow, talk to your doctor about adding a topical patch to your treatment.

The flurbiprofen patch is available in many countries. In the U.S., similar patches (like diclofenac gel) are already used for joint pain.

This combo isn’t experimental. It’s safe, accessible, and now — backed by real-world data.

You don’t need to wait for a new drug. Help may be closer than you think.

Study had limits

Only 64 people were included. The study wasn’t randomized — doctors chose the treatment, which can bias results. And it only followed patients for 3 months.

Larger, longer trials are needed. But for now, this real-world data is strong enough to guide care.

What happens next

No new trials are announced yet. But these results may push doctors to adopt this combo more widely — especially for patients who aren’t improving on pills alone.

Sometimes, progress isn’t about new miracles. It’s about using what we have — better.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveThe study is aimed to retrospectively compare the efficacy, safety, and impact on serum inflammatory markers between oral celecoxib combined with flurbiprofen hydrogel patch and oral celecoxib alone in the treatment of lateral epicondylitis.MethodsA retrospective cohort analysis was conducted on 64 patients diagnosed with lateral epicondylitis between January 2022 and December 2024. Patients were divided into two groups: the combined therapy group (oral celecoxib + topical flurbiprofen hydrogel patch, n = 32) and the single therapy group (oral celecoxib alone, n = 32). The primary outcome measures were Visual Analog Scale (VAS) scores and Patient-Rated Tennis Elbow Evaluation (PRTEE) scores measured at pre-treatment, 2 weeks, and 4 weeks of treatment. Secondary outcome measures included overall efficacy rate, effecting time, and 3-month recurrence rate. Serum inflammatory markers (tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP)) were measured and compared between the two groups at pre-treatment, 2 weeks, and 4 weeks. Adverse events were evaluated between two groups.ResultsPre-treatment characteristics were comparable between the two groups. Regarding clinical efficacy, at both 2 and 4 weeks post-treatment, the combined therapy group showed significantly lower VAS scores (2 weeks post-treatment: 3.9 ± 1.4 vs. 5.0 ± 1.5, P = 0.003; 4 weeks post-treatment: 2.2 ± 1.1 vs. 3.6 ± 1.3, P < 0.001) and PRTEE scores (2 weeks post-treatment: 37.8 ± 10.5 vs. 46.3 ± 12.1, P = 0.004; 4 weeks post-treatment: 21.0 ± 9.8 vs. 31.4 ± 10.9, P < 0.001) compared to the single therapy group. The combined therapy group also demonstrated a higher overall efficacy rate (81.3% vs. 59.4%, P = 0.049) and a faster effecting time (median: 4.0 days vs. 7.0 days, P = 0.003). Regarding inflammatory markers, at both 2 and 4 weeks post-treatment, serum levels of TNF-α, IL-6, and CRP in the combined therapy group were significantly reduced from pre-treatment. Specifically, at 4 weeks post-treatment, TNF-α levels were significantly lower in the combined therapy group (12.3 ± 3.5 pg/mL vs. 16.8 ± 4.1 pg/mL, P < 0.001), as were IL-6 levels (8.1 ± 2.9 pg/mL vs. 11.7 ± 3.3 pg/mL, P < 0.001) and CRP levels (5.2 ± 2.1 mg/L vs. 8.0 ± 2.8 mg/L, P < 0.001). In terms of safety, there was no significant difference in the overall incidence of adverse events (21.9% vs. 12.5%, P = 0.327) and the 3-month recurrence rate (15.6% vs. 34.4%, P = 0.085) between two groups.ConclusionFor lateral epicondylitis, the combination of oral celecoxib and topical flurbiprofen hydrogel patch is superior to oral celecoxib alone in alleviating pain, improving function, and reducing systemic inflammation. The combined therapy also increases the overall efficacy rate, reduces the effecting time, without increasing systemic adverse events. The combined regimen represents an effective and safe treatment option to offer benefits for clinical application.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.